Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 371

1.

Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.

Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR.

N Engl J Med. 2012 Aug 23;367(8):705-15. doi: 10.1056/NEJMoa1203208. Epub 2012 Jun 25.

2.

Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology.

Labourier E, Shifrin A, Busseniers AE, Lupo MA, Manganelli ML, Andruss B, Wylie D, Beaudenon-Huibregtse S.

J Clin Endocrinol Metab. 2015 Jul;100(7):2743-50. doi: 10.1210/jc.2015-1158. Epub 2015 May 12.

3.

An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.

McIver B, Castro MR, Morris JC, Bernet V, Smallridge R, Henry M, Kosok L, Reddi H.

J Clin Endocrinol Metab. 2014 Nov;99(11):4069-77. doi: 10.1210/jc.2013-3584. Epub 2014 Apr 29.

PMID:
24780044
4.

Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?

Kloos RT, Reynolds JD, Walsh PS, Wilde JI, Tom EY, Pagan M, Barbacioru C, Chudova DI, Wong M, Friedman L, LiVolsi VA, Rosai J, Lanman RB, Kennedy GC.

J Clin Endocrinol Metab. 2013 Apr;98(4):E761-8. doi: 10.1210/jc.2012-3762. Epub 2013 Mar 8.

PMID:
23476074
5.

Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology?

Yang SE, Sullivan PS, Zhang J, Govind R, Levin MR, Rao JY, Moatamed NA.

Cancer Cytopathol. 2016 Feb;124(2):100-9. doi: 10.1002/cncy.21624. Epub 2015 Sep 30.

6.

Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.

Lastra RR, Pramick MR, Crammer CJ, LiVolsi VA, Baloch ZW.

Cancer Cytopathol. 2014 Oct;122(10):737-44. doi: 10.1002/cncy.21455. Epub 2014 Aug 13.

7.

The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology.

Duick DS, Klopper JP, Diggans JC, Friedman L, Kennedy GC, Lanman RB, McIver B.

Thyroid. 2012 Oct;22(10):996-1001. doi: 10.1089/thy.2012.0180. Epub 2012 Aug 8.

8.

HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules.

Lappinga PJ, Kip NS, Jin L, Lloyd RV, Henry MR, Zhang J, Nassar A.

Cancer Cytopathol. 2010 Oct 25;118(5):287-97. doi: 10.1002/cncy.20095.

9.

Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.

Brauner E, Holmes BJ, Krane JF, Nishino M, Zurakowski D, Hennessey JV, Faquin WC, Parangi S.

Thyroid. 2015 Jul;25(7):789-96. doi: 10.1089/thy.2015.0049. Epub 2015 Jun 4.

PMID:
25962906
10.

Clinical diagnostic gene expression thyroid testing.

Steward DL, Kloos RT.

Otolaryngol Clin North Am. 2014 Aug;47(4):573-93. doi: 10.1016/j.otc.2014.04.009. Review.

PMID:
25041959
11.

Can a gene-expression classifier with high negative predictive value solve the indeterminate thyroid fine-needle aspiration dilemma?

Faquin WC.

Cancer Cytopathol. 2013 Mar;121(3):116-9. doi: 10.1002/cncy.21277. Epub 2013 Jan 30.

13.

A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration.

Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, Buitrago D, Cooper D, Zeiger MA, Zarnegar R, Elemento O, Fahey TJ 3rd.

Clin Cancer Res. 2012 Apr 1;18(7):2032-8. doi: 10.1158/1078-0432.CCR-11-2487. Epub 2012 Feb 20.

14.

Multicenter clinical experience with the Afirma gene expression classifier.

Alexander EK, Schorr M, Klopper J, Kim C, Sipos J, Nabhan F, Parker C, Steward DL, Mandel SJ, Haugen BR.

J Clin Endocrinol Metab. 2014 Jan;99(1):119-25. doi: 10.1210/jc.2013-2482. Epub 2013 Dec 20.

PMID:
24152684
15.

Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology.

Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding WE, LeBeau SO, Ohori NP, Seethala RR, Tublin ME, Yip L, Nikiforova MN.

Thyroid. 2015 Nov;25(11):1217-23. doi: 10.1089/thy.2015.0305. Epub 2015 Sep 10.

16.
17.

Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study.

Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, Palestini N, Ghigo E, Papotti M, Bussolati G, Martegani MP, Pantellini F, Carpi A, Giovagnoli MR, Monti S, Toscano V, Sciacchitano S, Pennelli GM, Mian C, Pelizzo MR, Rugge M, Troncone G, Palombini L, Chiappetta G, Botti G, Vecchione A, Bellocco R; Italian Thyroid Cancer Study Group (ITCSG).

Lancet Oncol. 2008 Jun;9(6):543-9. doi: 10.1016/S1470-2045(08)70132-3. Epub 2008 May 19.

PMID:
18495537
18.

Implications of follicular neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of thyroid nodules.

Goldstein RE, Netterville JL, Burkey B, Johnson JE.

Ann Surg. 2002 May;235(5):656-62; discussion 662-4.

19.

BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.

Adeniran AJ, Hui P, Chhieng DC, Prasad ML, Schofield K, Theoharis C.

Acta Cytol. 2011;55(6):570-5. doi: 10.1159/000333274. Epub 2011 Dec 9.

PMID:
22156468
20.

Molecular diagnostic testing and the indeterminate thyroid nodule.

Yip L.

Curr Opin Oncol. 2014 Jan;26(1):8-13. doi: 10.1097/CCO.0000000000000023. Review.

PMID:
24225416

Supplemental Content

Support Center